Skip to search formSkip to main contentSkip to account menu

otlertuzumab

A recombinant single-chain polypeptide engineered to exhibit the full binding and activity of an anti-CD37 monoclonal antibody with potential… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Otlertuzumab (TRU‐016) is a humanized anti‐CD37 protein therapeutic that triggers direct caspase‐independent apoptosis of… 
Review
2015
Review
2015
Introduction: Over the last few years, several new immunological drugs, particularly monoclonal antibodies (mAbs… 
2014
2014
SummaryPurpose CD37 is cell surface tetraspanin present on normal and malignant B cells. Otlertuzumab (TRU-016) is a novel… 
Review
2014
Review
2014
Introduction: Immunotherapy using mAbs is a safe and effective method for the treatment of chronic lymphocytic leukemia (CLL) and… 
2014
2014
Background: CD37 is a tetraspanin protein expressed on the surface of normal and transformed B cells across a wide range of… 
2014
2014
In this issue of Blood , Byrd et al present first-in-man data in chronic lymphocytic leukemia (CLL) using otlertuzumab (TRU-016… 
2014
2014
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in… 
2014
2014
Background: CD37 is a 50-55 kDa heavily glycosylated member of the tetraspanin superfamily of molecules. This cell surface… 
2013
2013
Background CD37 is a tetraspanin protein expressed on the surface of normal and transformed B-cells across a wide range of… 
2013
2013
Background CD37 is a tetraspanin protein expressed on the surface of normal and transformed B-cells across a wide range of…